In contrast, of the nine genes selected by the algorithm, DERL1, and FAM91A1’s expression levels are in the 99th percentile in the EFM192A cell line compared to other breast cancer cell lines and display correlation with breast cancers’ response to ibrutinib, including EFM192A (Fig. 5b). The gene discussed is DERL1; the disease is breast carcinoma.